Treatment, Medication & Supplement Directory
A comprehensive encyclopedia of medicines, chemotherapy protocols, targeted and immune therapies, supplements, Chinese herbal formulas, Traditional Chinese Veterinary Medicine (TCVM) approaches, and supportive-care options used or discussed in canine and feline tumor care. Directory entries explain what each option is, where it may fit, its evidence and safety boundaries, and what to discuss with a veterinarian; they are references, not individualized prescriptions or rankings.
Named profile Mesna in Veterinary Oncology: Uroprotection With Ifosfamide and CyclophosphamideRepresentative category illustration – no product packaging is shown.Mesna in Veterinary Oncology: Uroprotection With Ifosfamide and Cyclophosphamide
mesna (sodium 2-mercaptoethane sulfonate) is covered as protocol-linked uroprotective medicine; not antitumour therapy, with species, evidence, regulatory, safety, interaction and monitoring boundaries for a veterinarian-led decision.
Read more
Named profile Dexrazoxane in Veterinary Oncology: Anthracycline Rescue and CardioprotectionRepresentative category illustration – no product packaging is shown.Dexrazoxane in Veterinary Oncology: Anthracycline Rescue and Cardioprotection
dexrazoxane is covered as emergency extravasation antidote and selected anthracycline cardioprotectant, with species, evidence, regulatory, safety, interaction and monitoring boundaries for a veterinarian-led decision.
Read more
Named profile Furosemide as a Cyclophosphamide Uroprotection Adjunct in DogsRepresentative category illustration – no product packaging is shown.Furosemide as a Cyclophosphamide Uroprotection Adjunct in Dogs
furosemide used as a protocol adjunct is covered as loop diuretic used within selected canine cyclophosphamide protocols; not antitumour therapy, with species, evidence, regulatory, safety, interaction and monitoring…
Read more
Named profile H1 and H2 Blockade Around Mast-Cell Degranulation RiskRepresentative category illustration – no product packaging is shown.H1 and H2 Blockade Around Mast-Cell Degranulation Risk
H1-receptor and H2-receptor blocking companion medicines is covered as protocol-linked supportive medicines; not direct antitumour treatment, with species, evidence, regulatory, safety, interaction and monitoring boundaries for a veterinarian-led…
Read more